Deletion of the Prion Protein Does not Affect Erythropoiesis in a Mouse Model of Beta-Thalassemia

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 3213-3213
Author(s):  
Monique Gelderman-Fuhrmann ◽  
John Farrell ◽  
Martin Panigaj ◽  
Karel Holada ◽  
Jaroslav Vostal

Abstract Abstract 3213 The cellular prion protein (PrPc) is a highly conserved GPI-linked cell surface sialoglycoprotein which plays a key role in the pathogenesis of neurodegenerative prion diseases. Although PrPc is conserved across species, its normal function is not clearly understood. PrPc tissue distribution varies by cell type or by level of expression in different species. Circulating red blood cells (RBCs) in humans and mice have similar levels of PrPc and reports in the literature suggest that it has a role in survival of cells under stress conditions. We previously reported that an absence of PrPc in PrPc knock out (Prnp-/-) mice negatively influenced their response to acute anemia induced with phenylhydrazine (PHZ) (Zivny et al. 2008. Blood Cells, Molecules and Diseases. 40: 302–307). Prpn-/- mice displayed a reduction of erythroid cells and erythropoietin production suggesting the importance of PrPc expression for stress erythropoiesis. In order to further explore this observation, we mated chronically anemic β-thalassemic (th3/+) male mice (generously donated by Dr. M Sadelein, NY) with female Prnp-/- mice. Th3/+ mice have a defect in the β chain of hemoglobin and have lower hematocrits (HCT). Their offspring, heterozygous for PrPc (Prnp+/−), were genotyped and anemic th3/+ Prnp+/− males were mated with non-anemic (WT) Prnp+/− females to produce mice for the study. The PrPc genotype of two cohorts of offspring combined (n=127 total), Prnp+/+ (18%), Prpn+/− (56%) and Prnp-/- (26%), did not show significant deviation from a Mendelian distribution. Similarly, the proportion of Prnp-/- genotype among anemic th3/+ offspring (29.5%) was slightly higher than the proportion of Prnp+/+ genotype (18.1%), suggesting that PrPc deletion does not lead to higher in utero mortality of th3/+ mice. Evaluation of the microhematocrit at 12 weeks of age demonstrated decreased HCT levels of th3/+ mice (37.4±5.0% and 35.1±2.9%) in comparison to their WT siblings (51.6±2.5% and 49.1±3.5%). No significant differences were detected among different Prnp genotypes in both th3/+ and WT mice. In order to test if PrPc expression in these mice is important for the recovery from acute anemia, the th3/+ and the WT siblings of all PrPc genotypes (n=6 per group) were injected with PHZ (80 mg/kg). The following parameters were measured over a 7 day period using standard methods: HCT levels, plasma erythropoietin (EPO) levels, peripheral reticulocyte count, percentage of cells in the spleen expressing CD71, and the weight of animals and their spleens at the end of the study. On day 7 after induction of acute anemic stress, plasma EPO levels were higher in th3/+ animals compared to WT animals, 1125±48.4 pg/mL and 338±104.5 pg/mL respectively. The percent of erythroid precursor cells (CD71+) were lower in th3/+ (10.0±0.7%) than in WT (21.8±2.8%) splenocytes but the spleen sizes were larger in the th3/+ mice. Hematocrits were not different with statistical significance between th3/+ (28.8±0.6%) and WT (31.5±0.75%) animals on day 7, but circulating reticulocyte counts were higher in th3/+ (54.2±4.9% vs. 40.9±3.8%) animals. The PrPc genotype (Prnp+/+, Prnp+/− and Prnp-/-) did not affect the results in either the th3/+ or WT animals. Th3/+ animals were chronically anemic and had inefficient erythropoiesis which produced a lower percentage of CD71+ cells, in spite of higher levels of plasma EPO in response to similar levels of hypoxic stress as in the WT mice. However, the overall RBC production of th3/+ mice in response to acute hypoxia was maintained by a large spleen size. The prion protein deletion did not affect the percent of RBC precursors or the final RBC output. Thus, prion protein expression does not appear to influence RBC production in a chronically anemic mouse model. The findings and conclusions in this abstract have not been formally disseminated by the Food and Drug Administration and should not be construed to represent any Agency determination or policy. (GAUK86408, GACR 310/08/0878) Disclosures: No relevant conflicts of interest to declare.

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 2032-2032
Author(s):  
Hana Glierova ◽  
Martin Panigaj ◽  
Jana Semberova ◽  
Olga Janouskova ◽  
Eva Dvorakova ◽  
...  

Abstract Abstract 2032 Cellular prion protein (PrPc) plays a key role in pathogenesis of prion diseases, however, its physiologic function remains unclear. The involvement of PrPc in hematopoiesis was suggested by importance of its expression for self renewal and survival of long term repopulating hematopoietic stem cells. Prion diseases were shown to deregulate transcription of several erythroid genes and we have demonstrated reduction of erythroid cell and erythropoietin production in FVB PrP-/- (Zurich I) mice in response to acute anemia (Zivny J. et al. Blood Cells Mol Dis. 2008;40:302-307). In this study, we exploited different mouse models with manipulated level of PrPc expression to verify the role of PrPc in erythropoiesis. First set of experiments was carried out on PrP-/- (Zurich I) and Tga20 PrP over-expressing mice on a mixed C57Bl6/129Sv genetic background. Inbred C57Bl6 mice served as a wild type control (WT). Induction of acute anemia by phenylhydrazine (PHZ) in PrP-/- and WT mice (n=18) led to drop in the hematocrit (HCT) from 52.5±1.5 and 49.8±2.5% to 37.9± 1.0 and 41.9±3.0% after 24 h, respectively. The course of anemia was significantly deeper in PrP-/- mice at 72 h, 96 h and 120 h (p < 0.01) after PHZ administration. Plasma levels of erythropoietin (Epo) in response to anemia reached higher maximum levels in PrP-/- than WT mice (2250 vs. 1810 pg/mL) although rose more slowly. The level of Epo mRNA in kidneys increased approximately 30-fold in both, WT and PrP-/- mice, however, in WT mice peaked at 24 h whereas in KO mice at 96 h. We repeated the study with smaller groups of PrP-/- and Tga20 mice (n=9) and analysed samples 24 h and 96 h post anemia induction. Random PrP gene re-introduction in Tga20 mice rescued the animals from severe anemia. Decrease in HCT after PHZ administration was significantly lower in Tga20 comparing to PrP-/- mice and was accompanied by less elevated reticulocyte (RTC) count, plasma Epo level and level of Epo mRNA in kidneys. Next we studied the dynamics of unchallenged erythropoiesis in PrP-/-, Tga20 and WT mice by in vivo labelling of blood cells with NHS-biotin and subsequent flow cytometric analysis of relative numbers of newly produced non-labelled RBC. WT mice had significantly enhanced turnover of RBC with higher counts of non-labelled RBC comparing to PrP-/- during 46 days of chase (p < 0.05). Half- life of labeled RBC in WT mice was 20 days, but 32 and 30 days in PrP-/- and Tga20 mice, respectively. Tga20 mice displayed tendency to increased RBC turnover over PrP-/- mice, but the difference was significant only 2 and 33 days after initiation of the experiment. Having in mind possible limitations of experiments conducted in genetically modified inbred mice we have designed second set of experiments in more stringent animal models. We mated C57Bl6/129Sv PrP-/- mice with inbred C57Bl6 and outbred CD-1 mice. Heterozygotes in F1 generation were mated and their PrP -/-, PrP -/+ and PrP +/+ offspring used in the experiments. Anemia was induced by PHZ and blood was sampled from tail vein at defined time points and HCT and RTC count were analysed. In C57Bl6 crossbreeds we observed significantly higher starting HCT level in PrP-/- mice (p < 0.05) compared to PrP-/+ and PrP+/+ mice reaching 53.2±2.3, 50.0±2.1 and 49±2.9%, respectively. Similar decrease in HCT was observed for all PrP groups 24 h after PHZ administration, however, significant differences between PrP-/- and PrP+/+ mice were recorded at 48 h and 72 h. The recovery to normal HCT was again retarded in PrP-/- mice. RTC counts rose more rapidly in PrP+/+ mice after PHZ administration and declined to basal levels faster than in PrP-/- mice, the difference reached significance at 24 h, 48 h and 96 h. Dynamics of unchallenged erythropoiesis in C57Bl6 crossbreeds was similar in all three PrP genotypes with no significant differences in numbers of newly produced RBC during 57 days of the experiment. In CD-1 crossbreed mice no significant differences in HCT and RTC counts were detected after PHZ induced anemia among PrP-/-, PrP-/+ and PrP+/+ siblings. Also the dynamics of unchallenged erythropoiesis was similar in all PrP genotypes. To sum up, our data confirmed the role of PrPc in stress erythropoiesis in studied inbred mouse models. In outbred model the effect of PrP deletion on erythropoiesis seems to be compensated. (GACR310/08/0878, GAUK86408) Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 4648-4648
Author(s):  
Mo Yang ◽  
Fanyi Meng ◽  
Jie Yu Ye ◽  
Yue Xu ◽  
Bin Xiao ◽  
...  

Abstract Abstract 4648 We have demonstrated the thrombopoietic effects of Chinese Medicine Dang Gui Bu Xue Tong (DBT), a formula composed of Radix Angelicae Sinensis and Radix Astragali in a thrombocypenic mouse model (Yang M et al, J Ethnopharm 2009). In this study, we further test the effect of polysaccharide (APS) from the root of Radix Angelicae Sinensis (APS) in in-vivo thrombopoiesis and in in-vitro megakaryocytopoiesis. A myelosuppression and thrombocytopenia mouse model was treated with APS (10 mg/kg/day), thrombopoietin (TPO) and saline as control. Peripheral blood cells from APS, TPO and vehicle-treated samples were then counted in different time-points. Using the colony-forming unit (CFU) assays, we determined the effects of APS on the hematopoietic stem/progenitor cells and megakaryocytic lineages. Analyses of Annexin V, Caspase-3, and Mitochondrial Membrane Potential were also conducted in megakaryocytic cell line M-07e. Lastly, the effects of APS on cells treated with Ly294002, a Phosphatidylinositol 3-Kinse inhibitor and the effect of APS on the phosphorylation of AKT were further studied in megakaryocytic cells. Our results showed that APS significantly enhanced the platelets and other blood cells recovery and CFU formation in this model. Morphological examination of bone marrows showed that APS treatment significantly increased the recovery of the megakaryocytic series and other hematopoietic progenitor cells. We observed the antiapoptotic effects of APS on M-07e cells. Addition of Ly294002 alone increases the percentage of cells undergoing apoptosis. In contrast, additional of APS to Ly294002-treated cells reversed the percentage of cells undergoing apoptosis. Furthermore, addition of APS significantly increased the phosphorylation of AKT. Our studies demonstrate that APS promotes platelet recovery in the mouse model and has anti-apoptosis effect in megakaryocytic cells. This effect is likely to be mediated by the PI3K/AKT pathway. Disclosures: No relevant conflicts of interest to declare.


2010 ◽  
Vol 176 (3) ◽  
pp. 1409-1420 ◽  
Author(s):  
Petra Steinacker ◽  
Andreas Hawlik ◽  
Stefan Lehnert ◽  
Olaf Jahn ◽  
Stephen Meier ◽  
...  

Transfusion ◽  
2015 ◽  
Vol 55 (11) ◽  
pp. 2590-2596
Author(s):  
Hana Glier ◽  
Jan Simak ◽  
Martin Panigaj ◽  
Monique P. Gelderman ◽  
Jaroslav G. Vostal ◽  
...  

Transfusion ◽  
2007 ◽  
Vol 47 (12) ◽  
pp. 2223-2232 ◽  
Author(s):  
Karel Holada ◽  
Jan Simak ◽  
Paul Brown ◽  
Jaroslav G. Vostal

Transfusion ◽  
2010 ◽  
Vol 51 (5) ◽  
pp. 1012-1021 ◽  
Author(s):  
Martin Panigaj ◽  
Adela Brouckova ◽  
Hana Glierova ◽  
Eva Dvorakova ◽  
Jan Simak ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document